Treatment Options for Chronic Myeloid Leukemia

Fulltext (.pdf)

https://doi.org/10.54937/zs.2022.14.1.53-60

Autori/ Authors: Simona Liová, Miriam Tupá

In: Zdravotnícke štúdie

ISSN: 1337-723X

Ročník/ Volume: XIV

Číslo/ Issue: 1

Strany/ Page Range: 53-60

Rok vydania/ Publication Year: 2022

Jazyk/ Language: Slovak

Vydavateľ/ Publisher: VERBUM – vydavateľstvo Katolíckej univerzity v Ružomberku

Abstrakt/ Abstract: Chronic myeloid leukemia is a hematopoietic malignancy resulting from the transformation of a primitive hematopoietic cell. It is a clonal myeloproliferative disease characterized by the presence of the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22. CML is generally thought to develop from the transformation of primitive hematopoietic stem cells with the BCR-ABL fusion gene. The presence of a unique genetic abnormality with strong pathogenetic potential has enabled the development of specific pathological tyrosine kinase inhibitors. Their introduction into clinical practice, especially their effectiveness, have revolutionized the treatment management and prognosis of this disease, as evidenced by the median survival of patients diagnosed in the chronic phase.

Kľúčové slová/ Keywords:  Chronic myeloid leukemia. BCR-ABL. Treatment. Tyrosine kinase inhibitors.

Citácia/ How to cite:

LIOVÁ, Simona a TUPÁ, Miriam, 2022. Možnosti liečby chronickej myeloidnej leukémie. Zdravotnícke štúdie. Online. Roč. XIV, č. 1, s. 53-60. ISSN 1337-723X. Dostupné na: https://doi.org/10.54937/zs.2022.14.1.53-60

Toto dielo je publikované pod/ This work is licensed under a Creative Commons Attribution 4.0 International License.